We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Oncogene Used as Drug Transporter to Block Tumor Growth

By LabMedica International staff writers
Posted on 07 Mar 2018
Print article
Image: The 123B9 dimeric peptide (right panel) has a scorpion-like shape with two arms that bind to EphA2-expressing cancer cells and a tail (brown) comprising the cytotoxic chemotherapeutic agent paclitaxel. The compound recognizes the surface of cancer cells that are rich in EphA2 (labeled in red in the left panel) and deliver the cytotoxic agent (Photo courtesy of the Pellecchia Laboratory, University of California, Riverside).
Image: The 123B9 dimeric peptide (right panel) has a scorpion-like shape with two arms that bind to EphA2-expressing cancer cells and a tail (brown) comprising the cytotoxic chemotherapeutic agent paclitaxel. The compound recognizes the surface of cancer cells that are rich in EphA2 (labeled in red in the left panel) and deliver the cytotoxic agent (Photo courtesy of the Pellecchia Laboratory, University of California, Riverside).
A potent peptide-drug conjugate that targets the EphA2 (ephrin type-A receptor 2) oncogene was shown to reduce circulating cancer cells and metastases in breast cancer models.

EphA2 overexpression has been associated with metastasis of multiple cancer types, including melanoma, ovarian, prostate, lung, and breast cancer. Investigators at the University of California, Riverside (USA) had proposed employing chemotherapeutic peptide-drug conjugates (PDCs) using EphA2-targeting agents such as the YSA peptide or its optimized version 123B9. While their studies indicated that YSA- or 123B9-drug conjugates could selectively deliver cytotoxic drugs to cancer cells in vivo, the high concentrations of the agents that were required to bind the EphA2 receptor remained a limiting factor in developing these PDC for clinical purposes.

In overcoming these limitations, the investigators reported in the February 22, 2018, online edition of the Journal of Medicinal Chemistry that they had prepared a dimeric version of 123B9 capable of inducing receptor activation at nanomolar concentrations. In addition, they demonstrated that conjugation of dimeric 123B9 with the anticancer drug paclitaxel was very effective in targeting circulating tumor cells and inhibiting lung metastasis in breast cancer models.

"Once this novel tumor-homing agent binds to the EphA2 receptor, the oncogene functions as a cancer-specific molecular Trojan horse for paclitaxel, carrying the drug inside the cancel cell, killing the cell, and thwarting metastasis," said senior author Dr. Maurizio Pellecchia, professor of biomedical sciences at the University of California, Riverside. "Without the targeting agent, paclitaxel cannot hitch a ride on EphA2. Because this binding causes EphA2 internalization, we also sought to conjugate 123B9 with paclitaxel and thus direct the drug to migrating cancer cells."

"Our work predicts that reducing the number of circulating cancer cells produces less metastasis," said Dr. Pellecchia. "Indeed, in a second tumor model of metastatic breast cancer, we demonstrated that mice treated with the EphA2-targeting paclitaxel conjugate presented nearly no lung metastases, while a large numbers of lesions were observed in both untreated mice and in mice treated with just paclitaxel. The proof-of-concept studies we have obtained thus far are extremely encouraging, and we are confident that with proper support and efforts we could translate our findings into experimental therapeutics for a variety of solid tumors that are driven by EphA2 overexpression, including breast, lung, prostate, pancreatic and ovarian cancers."

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.